13F Holdings
中文EN

BDTX Black Diamond Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1701541 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-100.0%
TTM net income YoY-305.0%
TTM EPS YoY-305.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-41.1%
ROA-32.3%
ROIC (approx.)-49.8%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets23.8%
Debt / equity0.00x
Current ratio6.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$70.00M$0———
R&D expense$33.56M$51.31M$59.35M$64.44M$96.83M
SG&A expense$16.57M$27.47M$27.11M$28.39M$30.04M
Operating income$12.52M-$78.78M-$86.46M-$92.83M-$126.87M
Interest expense————$0
Pretax income$22.36M-$69.68M-$82.64M-$91.27M-$125.33M
Income tax$0$0$0$0$0
Net income$22.37M-$69.68M-$82.44M-$91.17M-$125.60M
EBITDA$12.85M-$78.44M-$86.02M-$92.32M-$126.67M
EPS (basic)0.39-1.27-1.88-2.52-3.47
EPS (diluted)0.39-1.27-1.88-2.52-3.47
Weighted avg. shares (diluted)57.56M55.03M43.95M36.33M36.19M
Balance sheet
Cash & equivalents$20.99M$37.26M$57.04M$35.48M$67.02M
Short-term investments$107.66M$62.14M$75.18M$88.49M$143.99M
Current assets$132.44M$101.18M$134.03M$127.71M$215.70M
PP&E, net$365,000$1.39M$1.73M$2.59M$3.04M
Total assets$143.01M$122.64M$158.57M$156.25M$247.68M
Current liabilities$15.73M$20.57M$19.65M$15.26M$23.64M
Total liabilities$30.80M$39.35M$41.83M$40.56M$51.78M
Shareholders' equity$112.21M$83.28M$116.74M$115.69M$195.90M
Shares outstanding57.14M56.64M51.65M36.43M36.23M
Cash flow statement
Operating cash flow$29.61M-$62.30M-$66.72M-$85.08M-$100.15M
Capital expenditure—$0$33,000$192,000$2.71M
Free cash flow—-$62.30M-$66.75M-$85.27M-$102.86M
Investing cash flow-$44.91M$16.97M$16.35M$53.37M$130.61M
Financing cash flow-$146,000$25.55M$71.93M$177,000$729,000
Depreciation & amortization$325,000$343,000$437,000$508,000$205,000
Stock-based compensation$6.63M$10.63M$9.60M$12.20M$14.04M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.